MedPlus Subsidiary Faces Drug License Suspensions at Two Telangana Stores
Optival Health Solutions, a subsidiary of MedPlus Health Services Limited, has received suspension orders for drug licenses at two stores in Telangana due to violations under the Drugs and Cosmetics Act. The Balanagar Ground Floor store faces a 2-day suspension with an estimated revenue loss of Rs. 0.48 lacs, while the 3rd Phase KPHB store faces a 5-day suspension with an estimated revenue loss of Rs. 1.28 lacs. The suspensions were issued on October 18, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. MedPlus has disclosed this information in compliance with SEBI regulations.
*this image is generated using AI for illustrative purposes only.
Medplus Health Services Limited , a prominent player in the Indian pharmacy retail sector, has reported that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores in Telangana. This development comes as a result of violations under the Drugs and Cosmetics Act, as determined by the Assistant Director of Drugs Control Administration.
Suspension Details
The suspensions affect two stores in Telangana:
| Store Location | Suspension Duration | Estimated Revenue Loss |
|---|---|---|
| Balanagar Ground Floor | 2 days | Rs. 0.48 lacs |
| 3rd Phase KPHB | 5 days | Rs. 1.28 lacs |
Regulatory Compliance
According to the LODR (Listing Obligations and Disclosure Requirements) data filed by MedPlus Health Services Limited, the suspension orders were received on October 18, 2025. The company has promptly disclosed this information in compliance with SEBI regulations, specifically citing:
- SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023
- SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024
Violation Details
The suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. While the specific nature of the violations has not been detailed in the disclosure, these regulations typically cover a wide range of compliance requirements for drug retailers, including proper storage, dispensing practices, and maintenance of records.
Impact Assessment
MedPlus has provided an initial assessment of the potential financial impact:
- The Balanagar Ground Floor store may face a revenue loss of approximately Rs. 0.48 lacs.
- The 3rd Phase KPHB store could see a revenue loss of around Rs. 1.28 lacs.
While these figures represent a relatively small portion of the company's overall operations, they underscore the importance of regulatory compliance in the pharmaceutical retail sector.
Company Response
MedPlus Health Services Limited has stated that the suspension details will be made available on the company's official website, as well as on the websites of BSE Limited and the National Stock Exchange of India Ltd. This transparency aligns with the company's obligations as a publicly listed entity.
The incident serves as a reminder of the strict regulatory environment in which pharmaceutical retailers operate and the potential consequences of non-compliance. As the healthcare sector continues to be under scrutiny, such regulatory actions highlight the ongoing challenges faced by companies in maintaining operational standards while ensuring public safety.
Historical Stock Returns for Medplus Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.68% | +3.11% | +0.58% | -10.63% | -4.54% | -27.49% |
18
